Julia K. Rotow, MD, on Concurrent Osimertinib Plus Gefitinib in First-Line Treatment of NSCLC

Posted: Wednesday, June 24, 2020

Julia K. Rotow, MD, of Dana-Farber Cancer Institute, discusses findings on the tolerability of combination therapy with osimertinib and gefitinib for first-line treatment of EGFR-mutated non–small cell lung cancer. She describes this dual TKI regimen, and whether this approach might be explored in other settings.